Article Text

Audit, research and guideline update
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
  1. Liam G Heaney1,
  2. Ratko Djukanovic2,
  3. Ashley Woodcock3,
  4. Samantha Walker4,5,
  5. John G Matthews5,
  6. Ian D Pavord6,
  7. Peter Bradding7,
  8. Robert Niven3,
  9. Chris E Brightling7,
  10. Rekha Chaudhuri8,
  11. Joseph R Arron5,
  12. David F Choy5,
  13. Douglas Cowan8,
  14. Adel Mansur9,
  15. Andrew Menzies-Gow10,
  16. Ian Adcock11,
  17. Kian F Chung11,
  18. Chris Corrigan12,
  19. Peter Coyle1,
  20. Timothy Harrison13,
  21. Sebastian Johnston11,
  22. Peter Howarth2,
  23. James Lordan14,
  24. Ian Sabroe15,
  25. Jeannette Bigler16,
  26. Dirk Smith16,
  27. Matthew Catley17,
  28. Richard May17,
  29. Lisa Pierre18,
  30. Chris Stevenson18,
  31. Glenn Crater19,
  32. Frank Keane20,
  33. Richard W Costello21,
  34. Val Hudson22,
  35. David Supple22,
  36. Tim Hardman23
  1. 1Centre of Infection and Immunity, The Queens's University of Belfast, Belfast, UK
  2. 2Academic Unit of Clinical and Experimental Sciences, University of Southampton, Southampton, UK
  3. 3Institute of Inflammation and Repair, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
  4. 4Asthma UK, London, UK
  5. 5Genentech Inc., South San Francisco, California, USA
  6. 6Nuffield Department of Medicine, The University of Oxford, Oxford, UK
  7. 7Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, UK
  8. 8Greater Glasgow Health Board, Glasgow, UK
  9. 9Heart of England NHS Foundation Trust, Birmingham, UK
  10. 10Royal Brompton & Harefield NHS Foundation Trust, London, UK
  11. 11Imperial College of Science, Technology and Medicine, London, UK
  12. 12Kings College London, London, UK
  13. 13University of Nottingham, Nottingham, UK
  14. 14The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK
  15. 15School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
  16. 16Amgen Inc., Thousand Oaks, California, USA
  17. 17Astra Zeneca, London, UK
  18. 18Jannsen Research & Development LLC, London, UK
  19. 19Aerocrine AB, Solna, Sweden
  20. 20Vitalograph Inc, Ennis, Ireland
  21. 21Department of Medicine, Royal College of Surgeons Ireland, Dublin, Ireland
  22. 22Public and Patient Representative, London, UK
  23. 23Niche Science & Technology, Richmond, UK
  1. Correspondence to Professor Liam G Heaney, Centre for Infection and Immunity, Queen's University of Belfast, Level 8, Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, UK; l.heaney{at}qub.ac.uk

Abstract

The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

  • Asthma Mechanisms

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.